[MOL] Some good information.... [01777] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Some good information....



http://www.e-topics.com/index.asp?layout=topic_news&userID=199912271429556.936282E-02&topic=592&display=Oncology
 
Viragen and the U.K.'s Cancer Research Campaign Collaborate To Develop a Cancer Vaccine
Viragen, Inc. , announced today that its subsidiary, Viragen Ltd., in collaboration with the University of Nottingham and Cancer Research Campaign Technology has signed an agreement to develop a new cancer vaccine therapy for the treatment of several indications, including breast, ovarian and colorectal cancers.[PR Newswire]

[B] FULL/ Viragen, UK university to develop cancer vaccine therapy
New York--Jul 27--Viragen Inc.'s Viragen Scotland unit will collaborate with the University of Nottingham and Cancer Research Campaign Technology, a unit of Cancer Research Campaign, a U.K. charity, to develop a new cancer vaccine therapy for the treatment of breast, ovarian and colorectal cancers.[Bridge Information Systems, Inc.]

Genetronics Announces Return of Rights From Ethicon Endo-Surgery
Genetronics Biomedical Limited, San Diego, announced today that Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, has elected to exercise its discretionary right to terminate without cause the Licensing and Development Agreement and the Supply Agreement it entered into with Genetronics, Inc.[Canada NewsWire]

[B] FULL/ Tularik Inc. begins Phase I/II T67 carcinoma trial
New York--July 27-- Tularik Inc. has initiated phase I/II efficacy study for its anti-cancer drug candidate, T67, in patients with hepatocellular carcinoma . Many tumors, which have become resistant to other anti-cancer drugs, were found to be vulnerable to T67 in pre-clinical experiments.[Bridge Information Systems, Inc.]

SpectraSCIENCE Receives ISO 9001 Certification
SpectraSCIENCE, Inc. announced today that it received ISO 9001 Certification from its European Notified Body.[Business Wire]

Tularik Announces the Initiation of an Efficacy Study in Patients With Hepatocellular Carcinoma
Tularik Inc. today announced the initiation of a phase I/II efficacy study for its anti-cancer drug candidate, T67, in patients with hepatocellular carcinoma .[PR Newswire]

Nature Immunology Reports Antigenics' Sequencing of Heat Shock Protein Receptor A Critical Switch in Regulating the Immune System
A receptor that controls the ability of the body's immune system to combat disease has been discovered. The receptor, CD91, has been sequenced and identified as a heat shock protein receptor by Pramod K Srivastava, Ph.D.[PR Newswire]

THE HINDU/ Milestone in colon cancer treatment
A long-awaited study suggests that a class of asprin-like compounds could help prevent colon cancer.[All Material Subject to Copyright]

SMITHKLINE BEECHAM/ Coulter Pharmaceutical and SmithKline Beecham expand proprietary position with second U.S. patent grant this year
Coulter Pharmaceutical and SmithKline Beecham today announced that the U.S. Patent and Trademark Office has issued another patent relating to CD20 antibody therapy for the treatment of lymphoma.[M2 Communications, Inc.]

[B] FULL/ Johnson & Johnson unit ends license pact with Genetronics
New York--Jul 26--Johnson & Johnson's unit Ethicon Endo-Surgery Inc. terminated a licensing, development and supply agreement it had entered into with Genetronics Inc.[Bridge Information Systems, Inc.]

We invite you to take a look at our Album.                                               
www.angelfire.com/sc/molangels/index.html
 
  ( Very informational, good tips, Molers pictures, art work and much more....

spacer.gif